The Board of Directors hereby notifies that the transformation through merger of Bulgarian Rose – Sevtopolis AD in Sopharma AD has been registered with the Commercial Register with number 20150226134200. 

The registered capital of Sopharma AD is 134 797 899 BGN.Sopharma AD is now undertaking all necessary actions for registration of the new issuance of 2 797 899 shares, with nominal value of 1.00 BGN with the Central Depository AD.

SOPHARMA AD hereby informs that from 26 February 2015 up to and including 4 March 2015 the Company bought 1 000 own shares representing 0.00076% of the share capital of the Company, at a total value of 3 280.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 147 056, representing 3.90% of the share capital of the Company.

Sopharma AD (the “Company”) announces that on 5 March 2015 the Company bought 605 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 30.42%.

Sopharma AD notifies that for February 2015 the Company recorded a decrease of sales revenues of 16% compared to the same month of 2014, including 14% increase of domestic sales and 28% decrease of export sales. In February, the Russian market returned to the normal pace of sales, corresponding to this time of the year. The situation in Ukraine still restricts exports to this market.

For the two months of this year, revenues from sales decreased by 29% compared to the same period of 2014, including 12% increase of domestic sales and a 44% decrease of export sales.

The Board of directors of Sopharma AD hereby notifies that as part of the process related to the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD the company has undertaken the registration of the capital increase in the Central Depository AD.

Sopharma AD (the “Company”) announces that on 6 March 2015 the Company bought 458 250 shares from the capital of Momina krepost AD. After this transaction, the share of Sopharma AD in the capital of Momina krepost AD increased to 80.09%.

SOPHARMA AD hereby informs that from 5 March 2015 up to and including 11 March 2015 the Company bought 900 own shares representing 0.00067% of the share capital of the Company, at a total value of 2 970.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.30 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 147 956, representing 3.82% of the share capital of the Company.

Sopharma AD (the “Company”) announces that on 19 March 2015 the Company received Notifications for disclosure of share participation under art. 145 of POSA from Donev Investments Holding AD, Telecomplect Invest AD and Telso AD for change in their share participation in Sopharma AD due to the capital increase of Sopharma AD through the merger of Bulgarian Rose Sevtopolis AD.

SOPHARMA AD hereby informs that from 19 March 2015 up to and including 25 March 2015 the Company bought 15 200 own shares representing 0.011% of the share capital of the Company, at a total value of 52 440.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 163 156, representing 3.83% of the share capital of the Company.

TO THE EMPLOYEES OF SOPHARMA AD

Dear Madams and Sirs,

In relation with the requirement of art. 151, par. 3 of POSA, with the current letter we present a draft tender offer for the purchase of all shares of the other shareholders of Momina Krepost AD by the majority shareholder Sopharma AD. The following attachments have been added to the draft tender offer:

1. Current certificate of registration in the Commercial Register of the tender offeror Sopharma AD;